N/A N=131 Randomized Health Services Research

Pilot Evaluation of Hospice Decision Support Tools

Hospice · End-of-life Decision Making · Hospice Decision Making

Bottom Line

View on ClinicalTrials.gov: NCT03794700 ↗

Enrolled (actual)

131

Serious AEs

—

Results posted

Aug 2022

Primary outcome: Primary: Hospice Knowledge Scale — 18; 17 score on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Hospice Decision Aids (Other)
Age: Older Adult · 65+ yrs
Sex: All
Sponsor: University of Colorado, Denver
Primary completion: Mar 2020

Outcome Measures

Outcome	Result	p-value
PRIMARY Hospice Knowledge Scale	18; 17	—
PRIMARY Hospice Beliefs and Attitudes Scale	32; 33	—
PRIMARY Decision Self Efficacy Scale	87; 94	—

Summary

The goal of this project is to determine the feasibility and acceptability of a hospice decision aid among a diverse population of older adults at multiple stages of illness (Aim 1) and to determine the preliminary efficacy of the hospice decision aid on decision quality, hospice knowledge, and values-concordance (Aim 2). By testing the feasibility, acceptability, and preliminary efficacy of a novel hospice Patient Decision Aid (PTDa) in a diverse population of older adults, additionally the study will simultaneously explore barriers to PtDA implementation in both an outpatient primary care and inpatient palliative care setting. The study will also gather sufficient pilot data to support a subsequent effectiveness/implementation trial and thus address the absence of quality of SDM interventions for end-of-life care decision-making.

Eligibility Criteria

Inclusion Criteria

65 or older.
At least one life-limiting illness or syndrome.

Exclusion Criteria

Non-English speakers.
Patients with cognitive Impairments preventing ability to provide informed consent.
Patients on isolation precautions due to resistant bacteria or impaired immune function.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03794700). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.